恩替卡韦治疗肾肝移植受者中对阿德福韦耐药的乙型肝炎病毒感染。
Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients.
作者信息
Kamar Nassim, Milioto Olivier, Alric Laurent, El Kahwaji Labib, Cointault Olivier, Lavayssière Laurence, Sauné Karine, Izopet Jacques, Rostaing Lionel
机构信息
Nephrology, Dialysis, and Multiorgan Transplant Unit, University Hospital, CHU Rangueil, 31059 Toulouse Cédex 9, France.
出版信息
Transplantation. 2008 Aug 27;86(4):611-4. doi: 10.1097/TP.0b013e3181806c8c.
The aim of our study was to assess the efficacy and safety of entecavir in kidney- and liver-transplant recipients with chronic hepatitis B virus (HBV) infection. Ten male transplant patients with chronic HBV infection (eight kidney- and two liver-transplant patients), who have become adefovir (n=9) or lamivudine-resistant (n=1) were given entecavir at 0.5 to 1 mg/d. All patients were HBs Ag positive: six were HBe Ag(-)/HBe Ab(+), and four were HBe Ag(+)/HBe Ab(-). After a median follow-up of 16.5 months, entecavir therapy was associated with a significant decrease in HBV DNA viral load, that is, 3.86 (2.71-6.46) log10 copies/mL at baseline down to 2.94 (2.15-4) log10 copies/mL at last follow-up (P=0.004). Rate of HBV DNA clearance was 50% in both HBeAg(+) and HBeAg(-) patients. There were no significant changes in renal function or hematological parameters. This study demonstrates that entecavir therapy is safe and efficient in HBV(+) organ-transplant patients.
我们研究的目的是评估恩替卡韦对慢性乙型肝炎病毒（HBV）感染的肾移植和肝移植受者的疗效和安全性。10例慢性HBV感染的男性移植患者（8例肾移植患者和2例肝移植患者），已对阿德福韦耐药（n = 9）或拉米夫定耐药（n = 1），给予恩替卡韦0.5至1mg/d。所有患者HBs Ag均为阳性：6例HBe Ag（-）/HBe Ab（+），4例HBe Ag（+）/HBe Ab（-）。中位随访16.5个月后，恩替卡韦治疗与HBV DNA病毒载量显著下降相关，即基线时为3.86（2.71 - 6.46）log10拷贝/mL，末次随访时降至2.94（2.15 - 4）log10拷贝/mL（P = 0.004）。HBeAg（+）和HBeAg（-）患者的HBV DNA清除率均为50%。肾功能或血液学参数无显著变化。本研究表明，恩替卡韦治疗对HBV（+）器官移植患者安全有效。
Zotero 插件